Humana Inc. $HUM Shares Sold by Bailard Inc.

Bailard Inc. cut its stake in Humana Inc. (NYSE:HUM) by 5.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,937 shares of the insurance provider’s stock after selling 305 shares during the period. Bailard Inc.’s holdings in Humana were worth $1,207,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of HUM. Cary Street Partners Investment Advisory LLC increased its stake in Humana by 63.9% in the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock valued at $31,000 after purchasing an additional 46 shares in the last quarter. Zions Bancorporation National Association UT acquired a new stake in Humana in the first quarter valued at $37,000. CVA Family Office LLC increased its position in shares of Humana by 63.4% in the second quarter. CVA Family Office LLC now owns 219 shares of the insurance provider’s stock valued at $54,000 after buying an additional 85 shares in the last quarter. Ransom Advisory Ltd acquired a new position in shares of Humana during the 1st quarter worth $66,000. Finally, Transamerica Financial Advisors LLC boosted its position in shares of Humana by 1,027.6% in the 1st quarter. Transamerica Financial Advisors LLC now owns 327 shares of the insurance provider’s stock worth $87,000 after buying an additional 298 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Price Performance

HUM stock opened at $236.75 on Friday. The stock has a market capitalization of $28.47 billion, a price-to-earnings ratio of 18.17, a price-to-earnings-growth ratio of 1.71 and a beta of 0.42. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.69. Humana Inc. has a 52-week low of $206.87 and a 52-week high of $315.35. The stock’s fifty day simple moving average is $272.46 and its 200-day simple moving average is $258.23.

Humana (NYSE:HUM) last released its earnings results on Wednesday, November 5th. The insurance provider reported $3.24 earnings per share for the quarter, topping the consensus estimate of $2.95 by $0.29. Humana had a return on equity of 13.67% and a net margin of 1.28%.The firm had revenue of $32.65 billion for the quarter, compared to the consensus estimate of $31.99 billion. During the same period in the prior year, the business posted $4.16 earnings per share. The firm’s revenue for the quarter was up 11.1% compared to the same quarter last year. Equities research analysts expect that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be given a $0.885 dividend. The ex-dividend date of this dividend is Friday, December 26th. This represents a $3.54 annualized dividend and a dividend yield of 1.5%. Humana’s dividend payout ratio (DPR) is currently 33.18%.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. Bank of America raised their target price on shares of Humana from $280.00 to $300.00 and gave the company a “neutral” rating in a report on Friday, October 10th. Sanford C. Bernstein increased their price target on shares of Humana from $269.00 to $341.00 and gave the company an “outperform” rating in a research report on Friday, September 5th. Robert W. Baird cut their price objective on Humana from $300.00 to $297.00 and set a “neutral” rating for the company in a research report on Friday, July 25th. Truist Financial lowered their target price on Humana from $300.00 to $285.00 and set a “hold” rating on the stock in a report on Monday. Finally, Mizuho raised their price target on Humana from $300.00 to $345.00 and gave the stock an “outperform” rating in a research report on Thursday, October 9th. Eight analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $298.39.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.